Corcept Therapeutics generates substantial multi-million-dollar annual revenues driven by robust commercial sales of its flagship cortisol-modulating medications. Recent financial reporting highlights annual revenues scaling past $760 million, with management updating full-year revenue guidance ranges between $900 million and over $1 billion, reflecting accelerated patient adoption and growing clinical recognition of hypercortisolism.